Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
|Videos|October 20, 2020
Complementing Your Psychotherapy
Author(s)Shawn Singh, JD
VistaGen Therapeutics CEO Shawn Singh discusses what he and VistaGen are doing to create and improve treatments that complement your practice.
Advertisement
Shawn K. Singh, JD, is the CEO of VistaGen Therapeutics, Inc.
To see more of what VistaGen is doing to improve the medicinal treatments for anxiety and depression, see
Advertisement
Related to this article
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
2
FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies
3
MDD Side Effect Profiles: Counseling, Adherence, and Suicidality Monitoring
4
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
5